Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 359-366 , April 2006

Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog

Received 13 October 2005 ,Revised 23 November 2005 ,Accepted 4 December 2005.

References 

  1. Hengstschläger M, Knöfler M, Müllner EW, Ogris E, Wintersberger E, Wawra E. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem. 1994;269:13836–13842
  2. Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson E. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res. 2004;64:6280–6286
  3. Barth RF, Yang W, Al-Madhoun AS, Johnsamuel J, Byun Y, Chandra S, et al. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors. Cancer Res. 2004;64:6287–6295
  4. Meyer GJ, Maecke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;31:1097–1104
  5. Diogo HP, Dias AR, Dhalla A, Minas da Piedade ME, Begley TP. Mechanistic studies on DNA photolyase. 4. The enthalpy of cleavage of a model photodimer. J Org Chem. 1991;56:7340–7341
  6. Moerlein SM, Welch MJ. The chemistry of gallium and indium as related to radiopharmaceutical production. Int J Nucl Med Biol. 1981;8:277–287
  7. Klein ATJ, Rösch F, Coenen HH, Qaim SM. Labelling of manganese-based magnetic resonance imaging (MRI) contrast agents with the positron emitter 51Mn, as exemplified by manganese-tetraphenyl-porphin-sulfonate (MnTPPS4). Appl Radiat Isot. 2005;62:711–720
  8. Adams DR, Perez C, Maillard M, Florent J-C, Evers M, Henin Y, et al. Preparation and anti-HIV activity of N-3-substituted thymidine nucleoside analogs. J Med Chem. 1997;40:550–1558
  9. Al-Madhoun AS, Tjarks W, Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem. 2004;4:341–350
  10. Breeman WAP, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917–920
  11. Velikyan I, Beyer GJ, Langström B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554–560
  12. Szilagyi E, Toth E, Kovacs Z, Platzek J, Radüchel B, Brücher E. Equilibria and formation kinetics of some cyclen derivative complexes of lanthanides. Inorg Chim Acta. 2000;298:226–234
  13. Ruser G, Ritter W, Maecke HR. Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111. Bioconjug Chem. 1990;1:345–349
  14. Shannon RD. Revised effective ionic radii and systemic studies of interatomic distances in halides and chalkogenides. Acta Cryst. 1976;A32:751–767
  15. Liu S. The role of coordination chemistry in the development of targetspecific radiopharmaceuticals. Chem Soc Rev. 2004;33:445–461
  16. Liu S, He Z, Hsieh W-Y, Fanwick PE. Synthesis, characterization and X-ray crystal structure if In(DOTA-AA) (AA=p-Aminoanilide): a model for 111In-labeled DOTA-biomolecule conjugates. Inorg Chem. 2003;42:8831–8837
  17. Liu S, Edwards DS. Synthesis and characterization of two 111In-labeled DTPA peptide conjugates. Bioconjug Chem. 2001;12:630–634
  18. Heppeler A, Froidevaux S, Maecke HR, Jermann E, Behe M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J. 1999;5:1974–1981
  19. Riesen A, Kaden TA, Ritter W, Maecke HR. Synthesis and X-ray structural characterisation of seven co-ordinate macrocyclic In3+ complexes with relevance to radiopharmaceutical applications. J Chem Soc Chem Commun. 1989;8:460–462
  20. Shields AF, Grierson JR, Dohmen BM, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  21. Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, et al. The uptake of 3′-deoxy-3′[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257–263
  22. Morin KW, Duan W, Xu L, Zhou A, Moharram S, Knaus EE, et al. Cytotoxicity and cellular uptake of pyrimidine nucleosides for imaging herpes simplex type-1 thymidine kinase (HSV-1 TK) expression in mammalian cells. Nucl Med Biol. 2004;31:623–630
  23. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D. Comparions of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808–818
  24. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 1995;67:155–186
  25. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiß S, Bangerter M, et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681–2687

PII: S0969-8051(05)00296-9

doi: 10.1016/j.nucmedbio.2005.12.010

Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 359-366 , April 2006

Article Tools

* Image Usage & Resolution